Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-10-28 Director's Dealing
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-10-28 English
DEFR14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, specifically an Amendment No. 1 to a definitive proxy statement for Serina Therapeutics, Inc. It relates to the 2025 Annual Meeting of Stockholders and includes detailed disclosures about a proposal concerning the issuance of common stock related to Convertible Notes and Warrants. The document references the original proxy statement and supplements it with additional information. The presence of terms like 'Proxy Statement,' 'Schedule 14A,' and the detailed discussion of shareholder proposals and voting matters clearly identify this as proxy solicitation material. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (5954 characters) and content confirm it is the actual amended proxy statement material, not just an announcement or a brief summary. Hence, the classification is PSI with high confidence.
2025-10-27 English
FORM 4
Director's Dealing
2025-10-21 English
Regulatory Filings 2025
Regulatory Filings
2025-10-14 English
FORM 4
Director's Dealing
2025-10-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 6, 2025. It announces the receipt of $5 million funding under a previously announced unsecured convertible note. The document references a prior Form 8-K filing for additional information on the convertible note. The content is an update on financing activity rather than a full financial report or earnings release. The document length is 3162 characters, which is relatively short and focused on a specific financing event. Therefore, it fits best under Capital/Financing Update (CAP).
2025-10-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.